Atossa Therapeutics, INC. (ATOS) SEC Filings — 2025

Filings

• Atossa Seeks Reverse Split to Avoid Nasdaq Delisting — DEF 14A · Dec 22, 2025
• Atossa Therapeutics Files 8-K — 8-K · Dec 4, 2025
• Atossa Therapeutics' Q3 Loss Widens Amid Soaring R&D Costs — 10-Q · Nov 12, 2025
• Atossa Therapeutics Files 8-K on Executive Changes — 8-K · Oct 14, 2025
• Atossa Therapeutics Files 8-K — 8-K · Sep 26, 2025
• Atossa Therapeutics Files 8-K Report — 8-K · Sep 8, 2025
• Atossa Therapeutics Faces Delisting Concerns — 8-K · Aug 21, 2025
• Atossa Therapeutics Files 8-K for Financial Reporting — 8-K · Aug 12, 2025
• Atossa Therapeutics Files Q1 2025 10-Q — 10-Q · May 13, 2025
• Atossa Therapeutics Files 8-K on Shareholder Vote Matters — 8-K · May 12, 2025
• Atossa Therapeutics Files 8-K Report — 8-K · Apr 7, 2025
• Atossa Therapeutics Executive Compensation Details — DEF 14A · Mar 26, 2025
• Atossa Therapeutics Files 2024 10-K — 10-K · Mar 25, 2025
• Atossa Therapeutics Files 8-K Report — 8-K · Mar 12, 2025
• Atossa Therapeutics Faces Delisting Concerns — 8-K · Feb 24, 2025
• Atossa Therapeutics Files 8-K — 8-K · Feb 4, 2025